Having stripped back its workforce, antibiotics biotech Spero Therapeutics continues to strip away its remaining pipeline. | ...

Early clinical trial results suggest that a groundbreaking new antibiotic drug could be a “massive game changer” for some patients suffering from chronic lower back pain.

The drug Blujepa, from drugmaker GSK, provides a new treatment option as bacteria increasingly become resistant to the ...

Drug-resistant infections—especially from deadly bacteria like tuberculosis and staph—are a growing global health crisis.

This antibiotic is the first new FDA-approved medication for urinary tract infections in decades, and meets the need for new ...

While most pharma companies have exited the antibiotics area, Japanese drugmaker Shionogi has stuck with it and has just expanded its pipeline with a deal to buy US biotech Qpex Biopharma.

A study shows continued increase in antibiotic resistance is not inevitable and offers new insights to help monitor drug ...

In seeking new antibiotic sources, researchers have turned to an unlikely source: a whiffy frog known as Odorrana andersonii.

The novel antibiotic class could be active against the vast majority of multidrug-resistant Enterobacterales infections.

Engineers have derived potent new antibiotics from a frog's secretions. The new molecules demonstrated capabilities on par with existing last-resort antibiotics, without harming human cells or ...